Cited by 2,175PARP inhibition in cancer therapyBRCA gene mutations in cancerAdvanced Breast Cancer Therapies

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Open access

Litton, Jennifer K., Rugo, Hope S., Ettl, Johannes, Hurvitz, Sara A., Gonçalves, Anthony, Lee, Kyung-Hun, Fehrenbacher, Louis, Yerushalmi, Rinat, Mina, Lida A., Martin, Miguel, Roché, Henri, Im, Young-Hyuck, Quek, Ruben G.W., Markova, Denka, Tudor, Iulia C., Hannah, Alison L., Eiermann, Wolfgang, Blum, Joanne L.·2018·New England Journal of Medicine

DOI 10.1056/nejmoa1802905PMC PMC10600918

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2). METHODS: We conducted a randomized, open-label, phase 3 trial in which patients with advanced breast cancer and a germline BRCA1/2 mutation were assigned, in a 2:1 ratio, to receive talazoparib (1 mg once daily) or standard single-agent therapy of the physician's choice (capecitabine, eribulin, gemcitabine, or vinorelbine in continuous 21-day cycles). The primary end point was progression-free survival, which was assessed by blinded independent central review. RESULTS: Of the 431 patients who underwent randomization, 287 were assigned to receive talazoparib and 144 were assigned to receive standard therapy. Median progression-free survival was significantly longer in the talazoparib group than in the standard-therapy group (8.6 months vs. 5.6 months; hazard ratio for disease progression or death, 0.54; 95% confidence interval [CI], 0.41 to 0.71; P<0.001). The interim median hazard ratio for death was 0.76 (95% CI, 0.55 to 1.06; P=0.11 [57% of projected events]). The objective response rate was higher in the talazoparib group than in the standard-therapy group (62.6% vs. 27.2%; odds ratio, 5.0; 95% CI, 2.9 to 8.8; P<0.001). Hematologic grade 3-4 adverse events (primarily anemia) occurred in 55% of the patients who received talazoparib and in 38% of the patients who received standard therapy; nonhematologic grade 3 adverse events occurred in 32% and 38% of the patients, respectively. Patient-reported outcomes favored talazoparib; significant overall improvements and significant delays in the time to clinically meaningful deterioration according to both the global health status-quality-of-life and breast symptoms scales were observed. CONCLUSIONS: Among patients with advanced breast cancer and a germline BRCA1/2 mutation, single-agent talazoparib provided a significant benefit over standard chemotherapy with respect to progression-free survival. Patient-reported outcomes were superior with talazoparib. (Funded by Medivation [Pfizer]; EMBRACA ClinicalTrials.gov number, NCT01945775 .).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1056/nejmoa1802905

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
Robson, M., Im, S.-A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., Delaloge, S., Li, W., Tung, N., Armstrong, A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1706450 · Cited by 3,294
Interpreting the significance of changes in health-related quality-of-life scores.
Osoba, D., Rodrigues, G., Myles, J., Zee, B. C.-Y., & Pater, J. L. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.139 · Cited by 3,016
PARP inhibitors: Synthetic lethality in the clinic
Lord, C. J., & Ashworth, A. (2017) · Science · doi:10.1126/science.aam7344 · Cited by 3,013
Design and analysis of randomized clinical trials requiring prolonged observation of each patient. I. Introduction and design
Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J., & Smith, P. G. (1976) · British Journal of Cancer · doi:10.1038/bjc.1976.220 · Cited by 2,294
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Murai, J., Huang, S.-Y. N., Das, B. B., Renaud, A., Zhang, Y., Doroshow, J. H., Ji, J. J., Takeda, S., & Pommier, Y. G. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-2753 · Cited by 2,276
PARP inhibition: PARP1 and beyond
Rouleau, M., Patel, A., Hendzel, M. J., Kaufmann, S. H., & Poirier, G. G. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2812 · Cited by 1,298
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A. N. J., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazińska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P. J., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 909
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Helleday, T. (2011) · Molecular Oncology · doi:10.1016/j.molonc.2011.07.001 · Cited by 895
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Murai, J., Huang, S.-Y. N., Renaud, A., Zhang, Y., Ji, J. J., Takeda, S., Morris, J., Teicher, B. A., Doroshow, J. H., & Pommier, Y. G. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-13-0803 · Cited by 777
Repeated assessment of results in clinical trials of cancer treatment
Haybittle, J. L. (1971) · British Journal of Radiology · doi:10.1259/0007-1285-44-526-793 · Cited by 519

Flagged first, then by citations

Show all 14 references

Research works printed but not linked: 1

Turner NC, Telli ML, Rugo HS, et al. Final results of a phase 2 study of talazoparib (TALA) following platinum or multiple cytotoxic regimens in advanced breast cancer patients (pts) with germline BRCA1/2 mutations (ABRAZO). Presented at the American Society of Clinical Oncology 2017 Annual Meeting, Chicago, June 2–6, 2017. abstract.

Sorted by citations

Items 301–400 of 1,000

PARP Inhibitors in Breast and Ovarian Cancer
Wang, S. S. Y., Jie, Y. E., Cheng, S. W., Ling, G. L., & Heong, V. Y. M. (2023) · Cancers · doi:10.3390/cancers15082357 · Cited by 60
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results
Schmid, P., Turner, N. C., Barrios, C. H., Isakoff, S. J., Kim, S., Sablin, M., Saji, S., Savas, P. S., Vidal, G. A., Oliveira, M., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2084 · Cited by 55
Therapeutic implications of germline genetic findings in cancer
Thavaneswaran, S., Rath, E. M., Tucker, K., Joshua, A. M., Hess, D., Pinese, M., Ballinger, M. L., & Thomas, D. M. (2019) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0179-3 · Cited by 56
Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis
Pogoda, K., Niwińska, A., Sarnowska, E. A., Nowakowska, D., Jagiełło-Gruszfeld, A., SIEDLECKI, J. A., & Nowecki, Z. I. (2020) · Journal of Oncology · doi:10.1155/2020/8545643 · Cited by 54
Prevalence of germline BRCA mutations in HER2-negative metastatic breast cancer: global results from the real-world, observational BREAKOUT study
O’Shaughnessy, J., Brezden‐Masley, C., Cazzaniga, M. E., Dalvi, T. B., Walker, G., Bennett, J., & Ohsumi, S. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01349-9 · Cited by 54
PI3K Inhibitors in Advanced Breast Cancer: The Past, The Present, New Challenges and Future Perspectives
Fuso, P., Muratore, M., D’Angelo, T., Paris, I., Carbognin, L., Tiberi, G., Pavese, F., Duranti, S., Orlandi, A., Tortora, G., et al. (2022) · Cancers · doi:10.3390/cancers14092161 · Cited by 55
Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective
Herzog, T. J., Vergote, I. B., Gomella, L. G., Milenkova, T., French, T., Tonikian, R., Poehlein, C. H., & Hussain, M. (2022) · European Journal of Cancer · doi:10.1016/j.ejca.2022.10.021 · Cited by 57
Triple-Negative Breast Cancer: Molecular Particularities Still a Challenge
Varzaru, V. B., Vlad, T., Popescu, R., Vlad, C. S., Moatar, A. E., & Cobec, I. M. (2024) · Diagnostics · doi:10.3390/diagnostics14171875 · Cited by 55
Diagnosis and Treatment of Breast Cancer in the Precision Medicine Era
Yan, J. Y., Liu, Z., Du, S., Li, J., Ma, L., & Li, L. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0904-0_5 · Cited by 54
Drug Repurposing for Triple-Negative Breast Cancer
Ávalos-Moreno, M., López-Tejada, A., Blaya-Cánovas, J. L., Cara, F. E., González-González, A., Lorente, J. A., Sánchez‐Rovira, P., & Granados-Principal, S. M. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040200 · Cited by 60
Genetic Landscape of Male Breast Cancer
Campos, F. A. B., Rouleau, É., Torrezan, G. T., Carraro, D. M., da Rocha, J. C. C., Mantovani, H. K., da Silva, L. R., Osório, C. A. B. D. T., Sanches, S. M., Caputo, S. M., et al. (2021) · Cancers · doi:10.3390/cancers13143535 · Cited by 58
PARP1 Inhibition Augments UVB-Mediated Mitochondrial Changes—Implications for UV-Induced DNA Repair and Photocarcinogenesis
Hegedűs, C., Boros, G., Fidrus, E., Kis, G. N., Antal, M., Juhász, T., Janka, E. A., Jankó, L., Paragh, G., Emri, G., et al. (2019) · Cancers · doi:10.3390/cancers12010005 · Cited by 51
PARP Inhibitors in Pancreatic Cancer
Brown, T. J., & Reiss, K. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000554 · Cited by 55
Clinical trials of immunotherapy in triple-negative breast cancer
Howard, F. M., Pearson, A. T., & Nanda, R. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06665-6 · Cited by 54
Association of Taxane Type With Patient-Reported Chemotherapy-Induced Peripheral Neuropathy Among Patients With Breast Cancer
Mo, H., Yan, X., Zhao, F., Teng, Y., Sun, X., Lv, Z., Cao, M., Zhao, J., Song, G., Pan, B., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.39788 · Cited by 55
Design and Synthesis of Poly(ADP-ribose) Polymerase Inhibitors: Impact of Adenosine Pocket-Binding Motif Appendage to the 3-Oxo-2,3-dihydrobenzofuran-7-carboxamide on Potency and Selectivity
Velagapudi, U. K., Langelier, M.-F., Delgado-Martín, C., Diolaiti, M. E., Bakker, S. T., Ashworth, A., Patel, B. A., Shao, X., Pascal, J. M., & Talele, T. T. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01709 · Cited by 53
Clinical outcomes with neoadjuvant versus adjuvant chemotherapy for triple negative breast cancer: A report from the National Cancer Database
Bagegni, N. A., Yu, T., & Ademuyiwa, F. O. (2019) · PLoS ONE · doi:10.1371/journal.pone.0222358 · Cited by 53
An update of new small-molecule anticancer drugs approved from 2015 to 2020
Liang, X., Wu, P., Yang, Q., Xie, Y., He, C., Yin, L., Yin, Z., Yue, G., Zou, Y., Li, L., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113473 · Cited by 53
Frequency of Pathogenic Germline Variants in Cancer-Susceptibility Genes in the Childhood Cancer Survivor Study
Kim, J., Gianferante, M., Karyadi, D. M., Hartley, S. W., Frone, M. N., Luo, W., Robison, L. L., Armstrong, G. T., Bhatia, S., Dean, M. C., et al. (2021) · JNCI Cancer Spectrum · doi:10.1093/jncics/pkab007 · Cited by 52
Genomic characterisation of hormone receptor-positive breast cancer arising in very young women
Luen, S. J., Viale, G., Nik‐Zainal, S., Savas, P. S., Kammler, R., Dell’Orto, P., Biasi, O., Degasperi, A., Brown, L. C., Láng, I., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2023.01.009 · Cited by 52
The role of DNA-demethylating agents in cancer therapy
Mehdipour, P., Murphy, T., & Carvalho, D. D. D. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2019.107416 · Cited by 55
Homologous recombination deficiency in breast cancer: Implications for risk, cancer development, and therapy
Ali, R., McIntosh, S., & Savage, K. I. (2020) · Genes Chromosomes and Cancer · doi:10.1002/gcc.22921 · Cited by 52
Cascade Genetic Testing for Hereditary Cancer Risk: An Underutilized Tool for Cancer Prevention
Whitaker, K. D., Obeid, E. I., Daly, M. B., & Hall, M. J. (2021) · JCO Precision Oncology · doi:10.1200/po.21.00163 · Cited by 56
Clinicopathological features and BRCA1 and BRCA2 mutation status in a prospective cohort of young women with breast cancer
Guzmán‐Arocho, Y. D., Rosenberg, S. M., Garber, J. E., Vardeh, H. G., Poorvu, P. D., Ruddy, K. J., Kirkner, G. J., Snow, C., Tamimi, R. M., Peppercorn, J. M., et al. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01597-2 · Cited by 51
Validation of the DNA Damage Immune Response Signature in Patients With Triple-Negative Breast Cancer From the SWOG 9313c Trial
Sharma, P., Barlow, W. E., Godwin, A. K., Parkes, E. E., Knight, L. A., Walker, S. M., Kennedy, R. D., Harkin, D. P., Logan, G. E., Steele, C., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00693 · Cited by 49
Association of Germline Genetic Testing Results With Locoregional and Systemic Therapy in Patients With Breast Cancer
Kurian, A. W., Ward, K. C., Abrahamse, P. H., Hamilton, A. S., Deapen, D., Morrow, M., Jagsi, R., & Katz, S. J. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2019.6400 · Cited by 51
Whole genome sequencing of breast cancer
Rossing, M., Sørensen, C. S., Ejlertsen, B., & Nielsen, F. C. (2019) · Apmis · doi:10.1111/apm.12920 · Cited by 52
Clinical Challenges in the Management of Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: A Literature Review
Nagaraj, G., & Ma, C. X. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01552-2 · Cited by 51
Incidence of myelodysplastic syndrome and acute myeloid leukemia in patients receiving poly-ADP ribose polymerase inhibitors for the treatment of solid tumors: A meta-analysis of randomized trials
Nitecki, R., Melamed, A., Gockley, A. A., Floyd, J. L., Krause, K. J., Coleman, R. L., Matulonis, U. A., Giordano, S. H., Lu, K. H., & Rauh‐Hain, J. A. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.03.011 · Cited by 49
Circular RNAs as Potential Biomarkers in Breast Cancer
Palma, F. D. E. D., Salvatore, F., Pol, J. G., Kroemer, G., & Maiuri, M. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030725 · Cited by 50
A two-step mechanism governing PARP1-DNA retention by PARP inhibitors
Xue, H., Bhardwaj, A., Yin, Y., Fijen, C., Ephstein, A., Zhang, L., Ding, X., Pascal, J. M., VanArsdale, T. L., & Rothenberg, E. (2022) · Science Advances · doi:10.1126/sciadv.abq0414 · Cited by 52
Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer
Nakhjavani, M., Hardingham, J. E., Palethorpe, H. M., Price, T. J., & Townsend, A. R. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e39 · Cited by 49
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib
de Haan, R., van Werkhoven, E. D., van den Heuvel, M. M., Peulen, H. M. U., Sonke, G. S., Elkhuizen, P. H. M., van den Brekel, M. W. M., Tesselaar, M. E. T., Vens, C., Schellens, J. H. M., et al. (2019) · BMC Cancer · doi:10.1186/s12885-019-6121-3 · Cited by 49
Expression of tumor-associated antigens in breast cancer subtypes
Curigliano, G., Bagnardi, V., Ghioni, M., Louahed, J., Brichard, V. G., Lehmann, F. F., Marra, A., Trapani, D., Criscitiello, C., & Viale, G. (2019) · The Breast · doi:10.1016/j.breast.2019.12.002 · Cited by 48
Application of Regulatory Cell Death in Cancer: Based on Targeted Therapy and Immunotherapy
Qi, X., Li, Q., Che, X., Wang, Q., & Wu, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.837293 · Cited by 48
PARP Inhibitors: A New Horizon for Patients with Prostate Cancer
Congregado, B., BELENCHON, I. R., Osman, I., Sáez, C., & López, R. A. M. (2022) · Biomedicines · doi:10.3390/biomedicines10061416 · Cited by 48
Olaparib maintenance versus placebo monotherapy in patients with advanced non-small cell lung cancer (PIN): A multicentre, randomised, controlled, phase 2 trial
Fennell, D. A., Porter, C., Lester, J. F., Danson, S. J., Blackhall, F. H., Nicolson, M. C., Nixon, L. S., Gardner, G. M., White, A., Griffiths, G. O., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101595 · Cited by 47
PARP Inhibitors for Breast Cancer: Germline BRCA1/2 and Beyond
Menezes, M. C. S., Raheem, F., Mina, L. A., Ernst, B. J., & Batalini, F. (2022) · Cancers · doi:10.3390/cancers14174332 · Cited by 48
Self-citation
RAGE inhibitor TTP488 (Azeliragon) suppresses metastasis in triple-negative breast cancer
Magna, M., Hwang, G. H., McIntosh, A. T., Drews‐Elger, K., Takabatake, M., Ikeda, A., Mera, B. J., Kwak, T., Miller, P., Lippman, M. E., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00564-9 · Cited by 48
PARP inhibitors: clinical development, emerging differences, and the current therapeutic issues
Murthy, P., & Muggia, F. M. (2019) · Cancer Drug Resistance · doi:10.20517/cdr.2019.002 · Cited by 49
Non-small cell lung cancer cells with deficiencies in homologous recombination genes are sensitive to PARP inhibitors
Ji, W., Weng, X., Xu, D., Cai, S., Lou, H., & Ding, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.11.050 · Cited by 44
Oligometastatic breast cancer: where are we now and where are we headed?—a narrative review
Kent, C. L., McDuff, S. G. R., & Salama, J. K. (2020) · Annals of Palliative Medicine · doi:10.21037/apm-20-1128 · Cited by 47
Druggable targets meet oncogenic drivers: opportunities and limitations of target-based classification of tumors and the role of Molecular Tumor Boards
Danesi, R., Fogli, S., Indraccolo, S., Re, M. D., Tos, A. P. D., Leoncini, L., Antonuzzo, L., Bonanno, L., Guarneri, V., Pierini, A., et al. (2021) · ESMO Open · doi:10.1016/j.esmoop.2020.100040 · Cited by 52
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
Agostinetto, E., Eiger, D., Punie, K., & de Azambuja, E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01038-6 · Cited by 47
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer
Hlevnjak, M., Schulze, M., Elgaafary, S., Fremd, C., Michel, L. L., Beck, K., Pfütze, K., Richter, D., Wolf, S., Horak, P., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00248 · Cited by 47
Advances in Therapeutic Approaches for Triple-Negative Breast Cancer
Mahtani, R. L., Kittaneh, M., Kalinsky, K. M., Mamounas, E. P., Badve, S., Vogel, C. L., Lower, E. E., Schwartzberg, L. S., & Pegram, M. D. (2020) · Clinical Breast Cancer · doi:10.1016/j.clbc.2020.12.011 · Cited by 45
Clinical Utility of Universal Germline Genetic Testing for Patients With Breast Cancer
Whitworth, P. W., Beitsch, P. D., Patel, R. P., Rosen, B. P., Compagnoni, G., Baron, P. L., Simmons, R. M., Brown, E. A., Gold, L. P., Holmes, D. R., et al. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.32787 · Cited by 47
Targeting BRCA Deficiency in Breast Cancer: What are the Clinical Evidences and the Next Perspectives?
Nicolas, E., Bertucci, F., Sabatier, R., & Gonçalvès, A. (2018) · Cancers · doi:10.3390/cancers10120506 · Cited by 47
Discrepancy in calculated and measured glomerular filtration rates in patients treated with PARP inhibitors
Molin, G. Z. D., Westin, S. N., Msaouel, P., Gomes, L., Dickens, A. S., & Coleman, R. L. (2019) · International Journal of Gynecological Cancer · doi:10.1136/ijgc-2019-000714 · Cited by 46
Rucaparib in patients presenting a metastatic breast cancer with homologous recombination deficiency, without germline BRCA1/2 mutation
Patsouris, A., Diop, K., Trédan, O., Nenciu, D., Gonçalvès, A., Arnedos, M., Sablin, M., Jézéquel, P., Jimenez, M., Droin, N. M., et al. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2021.09.028 · Cited by 46
Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
Liu, H., Bai, L., Huang, L., Ning, N., Li, L., Li, Y., Dong, X., Du, Q., Xia, M., Chen, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003468 · Cited by 46
Cyclin-Dependent Kinase 4/6 Inhibitor Outcomes in Patients With Advanced Breast Cancer Carrying Germline Pathogenic Variants in DNA Repair–Related Genes
Bruno, L. I., Ostinelli, A., Waisberg, F., Enrico, D. H., Ponce, C., Rivero, S. G., Blanco, A., Zarbá, M., Loza, M., Fabiano, V., et al. (2022) · JCO Precision Oncology · doi:10.1200/po.21.00140 · Cited by 49
Functions of Breast Cancer Predisposition Genes: Implications for Clinical Management
Yoshimura, A., Imoto, I., & Iwata, H. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23137481 · Cited by 48
Nationwide Trends and Determinants of Germline BRCA1/2 Testing in Patients With Breast and Ovarian Cancer
Lau‐Min, K. S., McCarthy, A. M., Nathanson, K. L., & Domchek, S. M. (2023) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7257 · Cited by 45
Emerging systemic therapy options beyond CDK4/6 inhibitors for hormone receptor-positive HER2-negative advanced breast cancer
Ma, J., Chan, J. J., Toh, C. H., & Yap, Y. S. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00578-3 · Cited by 49
Evidence to date: talazoparib in the treatment of breast cancer
Exman, P., Barroso‐Sousa, R., & Tolaney, S. M. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s184971 · Cited by 48
PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword
Csizmar, C. M., Saliba, A. N., Swisher, E. M., & Kaufmann, S. H. (2021) · Cancers · doi:10.3390/cancers13246385 · Cited by 45
Luminal androgen receptor breast cancer subtype and investigation of the microenvironment and neoadjuvant chemotherapy response
Thompson, K. J., Leon-Ferre, R. A., Sinnwell, J. P., Zahrieh, D., Suman, V. J., Metzger, O., Asad, S., Stover, D. G., Carey, L., Sikov, W. M., et al. (2022) · NAR Cancer · doi:10.1093/narcan/zcac018 · Cited by 45
How I treat HER2-low advanced breast cancer
Schlam, I. M., Tolaney, S. M., & Tarantino, P. (2023) · The Breast · doi:10.1016/j.breast.2023.01.005 · Cited by 45
Phosphoinositide 3-Kinase (PI3K) Inhibitors and Breast Cancer: An Overview of Current Achievements
Bertucci, A., Bertucci, F., & Gonçalvès, A. (2023) · Cancers · doi:10.3390/cancers15051416 · Cited by 45
A rationally designed ICAM1 antibody drug conjugate eradicates late-stage and refractory triple-negative breast tumors in vivo
Guo, P., Huang, J., Zhu, B., Huang, A. C., Jiang, L., Fang, J., & Moses, M. A. (2023) · Science Advances · doi:10.1126/sciadv.abq7866 · Cited by 44
BRCA genetic testing and counseling in breast cancer: how do we meet our patients’ needs?
Dubsky, P. C., Jackisch, C., Im, S., Hunt, K. K., Li, C., Unger, S., & Paluch–Shimon, S. (2024) · npj Breast Cancer · doi:10.1038/s41523-024-00686-8 · Cited by 49
Intracellular metal ion-based chemistry for programmed cell death
You, Y., Guo, Z., Wolter, T., & Hu, Q. (2025) · Chemical Society Reviews · doi:10.1039/d4cs00930d · Cited by 46
APE1 and NPM1 protect cancer cells from platinum compounds cytotoxicity and their expression pattern has a prognostic value in TNBC
Malfatti, M. C., Gerratana, L., Dalla, E., Isola, M., Damante, G., Loreto, C. D., Puglisi, F., & Tell, G. (2019) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-019-1294-9 · Cited by 44
Immunotherapy for the Treatment of Breast Cancer: Emerging New Data
Mina, L. A., Lim, S., Bahadur, S. W., & Firoz, A. T. (2020) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s184710 · Cited by 56
Self-citation
The evolving management of metastatic triple negative breast cancer
Malhotra, M. K., & Emens, L. A. (2020) · Seminars in Oncology · doi:10.1053/j.seminoncol.2020.05.005 · Cited by 41
Combination Therapy and Nanoparticulate Systems: Smart Approaches for the Effective Treatment of Breast Cancer
Gadag, S., Sinha, S., Nayak, Y., Garg, S., & Nayak, U. Y. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12060524 · Cited by 46
Canonical and Noncanonical Roles of Fanconi Anemia Proteins: Implications in Cancer Predisposition
Milletti, G., Strocchio, L., Pagliara, D., Girardi, K., Carta, R., Mastronuzzi, A., Locatelli, F., & Nazio, F. (2020) · Cancers · doi:10.3390/cancers12092684 · Cited by 46
Prognostic and predictive parameters in breast pathology: a pathologist's primer
Allison, K. H. (2020) · Modern Pathology · doi:10.1038/s41379-020-00704-7 · Cited by 46
The role of PARP inhibitors in BRCA mutated pancreatic cancer
Chi, J., Chung, S. Y., Parakrama, R. Y., Fayyaz, F., Jose, J., & Saif, M. W. (2021) · Therapeutic Advances in Gastroenterology · doi:10.1177/17562848211014818 · Cited by 47
PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
Vanacker, H., Harter, P., Labidi‐Galy, S. I., Banerjee, S. N., Oaknin, A., Lorusso, D., & Ray-Coquard, I. L. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102255 · Cited by 46
Breast cancer management in 2021: A primer for the obstetrics and gynecology
Fleege, N. M. G., & Cobain, E. F. (2022) · Best Practice & Research Clinical Obstetrics & Gynaecology · doi:10.1016/j.bpobgyn.2022.02.004 · Cited by 45
Personalized treatment in metastatic triple‐negative breast cancer: The outlook in 2020
Azim, H. A., Ghosn, M. G., Oualla, K., & Kassem, L. M. H. (2019) · The Breast Journal · doi:10.1111/tbj.13713 · Cited by 43
Major clinical research advances in gynecologic cancer in 2018
Kim, M., Suh, D. H., Lee, K.-H., Eom, K., Toftdahl, N. G., Mirza, M. R., & Kim, J. (2019) · Journal of Gynecologic Oncology · doi:10.3802/jgo.2019.30.e18 · Cited by 43
Self-citation
PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches
Barayan, R., Ran, X., & Lok, B. H. (2020) · Journal of Thoracic Disease · doi:10.21037/jtd.2020.03.89 · Cited by 43
Modeling and targeting of erythroleukemia by hematopoietic genome editing
Iacobucci, I., Qu, C., Varotto, E., Janke, L. J., Xu, Y., Seth, A., Shelat, A. A., Friske, J. D., Fukano, R., Yu, J., et al. (2021) · Blood · doi:10.1182/blood.2020009103 · Cited by 44
PARP inhibitors in head and neck cancer: Molecular mechanisms, preclinical and clinical data
Moutafi, M. K., Economopoulou, P., Rimm, D. L., & Psyrri, A. K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105292 · Cited by 45
The emerging role of RNA N6-methyladenosine methylation in breast cancer
Zheng, F., Du, F., Zhao, J., Wang, X. L., Si, Y., Peng, J., Qian, H., Xu, B., & Yuan, P. (2021) · Biomarker Research · doi:10.1186/s40364-021-00295-8 · Cited by 42
Biomarkers beyond BRCA: promising combinatorial treatment strategies in overcoming resistance to PARP inhibitors
Chu, Y., Yam, C., Yamaguchi, H., & Hung, M. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00870-7 · Cited by 47
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy
Huang, J.-L., Chang, Y.-T., Hong, Z.-Y., & Lin, C.-S. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063238 · Cited by 42
SUMOylation of HNRNPA2B1 modulates RPA dynamics during unperturbed replication and genotoxic stress responses
Zhu, S., Hou, J., Gao, H., Hu, Q., Kloeber, J. A., Huang, J., Zhao, F., Zhou, Q., Luo, K., Wu, Z., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.01.003 · Cited by 42
Phase II DORA Study of Olaparib with or without Durvalumab as a Chemotherapy-Free Maintenance Strategy in Platinum-Pretreated Advanced Triple-Negative Breast Cancer
Tan, T. J., Sammons, S. L., Im, Y., She, L., Mundy, K., Bigelow, R., Traina, T. A., Anders, C. K., Yeong, J. P.-S., Renzulli, E., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2513 · Cited by 42
Self-citation
Poly(ADP-Ribose) Polymerase (PARP) Inhibitors for Cancer Therapy: Advances, Challenges, and Future Directions
Bondar, D., & Karpichev, Y. (2024) · Biomolecules · doi:10.3390/biom14101269 · Cited by 44
Blocking c-Met and EGFR reverses acquired resistance of PARP inhibitors in triple-negative breast cancer.
Chu, Y., Yam, C., Chen, M., Chan, L.-C., Xiao, M., Wei, Y., Yamaguchi, H., Lee, P., Han, Y., Nie, L., et al. (2020) · PubMed Central · Cited by 42
Self-citation
Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma
Ewing, A., Meynert, A. M., Churchman, M., Grimes, G. R., Hollis, R. L., Herrington, C. S., Rye, T., Bartos, C., Croy, I., Ferguson, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4068 · Cited by 40
Endocrine Treatment for Breast Cancer Patients Revisited—History, Standard of Care, and Possibilities of Improvement
Nabieva, N., & Fasching, P. A. (2021) · Cancers · doi:10.3390/cancers13225643 · Cited by 45
Anti‐tumoural activity of the G‐quadruplex ligand pyridostatin against BRCA1/2‐deficient tumours
Groelly, F. J., Porru, M., Zimmer, J., Benainous, H., Visser, Y. D., Kosova, A. A., Vito, S. D., Serra, V., Ryan, A. J., Leonetti, C., et al. (2022) · EMBO Molecular Medicine · doi:10.15252/emmm.202114501 · Cited by 43
Role of PARP Inhibitors in Cancer Immunotherapy: Potential Friends to Immune Activating Molecules and Foes to Immune Checkpoints
Franzese, O., & Graziani, G. (2022) · Cancers · doi:10.3390/cancers14225633 · Cited by 44
Recommendations for the use of next-generation sequencing in patients with metastatic cancer in the Asia-Pacific region: a report from the APODDC working group
Loong, H. H.-F., Shimizu, T., Prawira, A., Tan, A. C., Tran, B., Day, D., Tan, D. S. P., Ting, F. I. L., Chiu, J. W. Y., Hui, M. N., et al. (2023) · ESMO Open · doi:10.1016/j.esmoop.2023.101586 · Cited by 46
BRCA1/2 Mutations and Breast/Ovarian Cancer Risk: A New Insights Review
Pourmasoumi, P., Moradi, A., & Bayat, M. (2024) · Reproductive Sciences · doi:10.1007/s43032-024-01666-w · Cited by 46
The treatment landscape of triple-negative breast cancer
Hu, Y., Wang, C., Liang, H., Li, J., & Yang, Q. (2024) · Medical Oncology · doi:10.1007/s12032-024-02456-9 · Cited by 42
Recommendations for Advancing the Diagnosis and Management of Hereditary Breast and Ovarian Cancer in Brazil
Achatz, M. I., Caleffi, M. M., Guindalini, R. S. C., Moretti‐Marques, R., Nogueira‐Rodrigues, A., & Ashton‐Prolla, P. (2020) · JCO Global Oncology · doi:10.1200/jgo.19.00170 · Cited by 41
The advance of adjuvant treatment for triple-negative breast cancer
Ge, J., Zuo, W., Chen, Y., Shao, Z., & Yu, K. (2021) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2020.0752 · Cited by 45
CDK4/6 inhibitors: A potential therapeutic approach for triple negative breast cancer
Saleh, L., Wilson, C., & Holen, I. (2021) · MedComm · doi:10.1002/mco2.97 · Cited by 40
Targeting the ALK–CDK9-Tyr19 kinase cascade sensitizes ovarian and breast tumors to PARP inhibition via destabilization of the P-TEFb complex
Chu, Y., Chen, M., Wei, Y., Lee, H., Xia, W., Wang, Y., Yam, C., Hsu, J. L., Wang, H.-L., Chang, W., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00438-2 · Cited by 40
Prevalence of women breast cancer
SALMAN, R. A. (2023) · Cellular Molecular and Biomedical Reports · doi:10.55705/cmbr.2023.384467.1095 · Cited by 40
“Diagnostic and Prognostic Biomarkers of Luminal Breast Cancer: Where are We Now?”
Holler, A., Nguyen-Sträuli, B. D., Frauchiger-Heuer, H., & Ring, A. (2023) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s340741 · Cited by 47
PARP Inhibitors in the Treatment of Early Breast Cancer: The Step Beyond?
Gonçalvès, A., Bertucci, A., & Bertucci, F. (2020) · Cancers · doi:10.3390/cancers12061378 · Cited by 40
Application and reflection of genomic scar assays in evaluating the efficacy of platinum salts and PARP inhibitors in cancer therapy
Gou, R., Dong, H., & Lin, B. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118434 · Cited by 42
Genetic Counseling and Testing in African American Patients With Breast Cancer: A Nationwide Survey of US Breast Oncologists
Ademuyiwa, F. O., Salyer, P., Tao, Y., Luo, J., Hensing, W. L., Afolalu, A., Peterson, L. L., Weilbaecher, K., Housten, A. J., Baumann, A. A., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01426 · Cited by 40

Authors: Litton, J. K., Rugo, H. S., Ettl, J., Hurvitz, S. A., Gonçalves, A., Lee, K.-H., Fehrenbacher, L., Yerushalmi, R., Mina, L. A., Martin, M., Roché, H., Im, Y.-H., Quek, R. G. W., Markova, D., Tudor, I. C., Hannah, A. L., Eiermann, W., & Blum, J. L.
Affiliations: Kaiser Permanente (US)
From the University of Texas M.D. Anderson Cancer Center, Houston (J.K.L.), and the Texas Oncology–Baylor Charles A. Sammons Cancer Center, US Oncology Network, Dallas (J.L.B.) — both in Texas; University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center (H.S.R.), and Pfizer (R.G.W.Q., D.M., I.C.T., A.L.H.), San Francisco, University of California, Los Angeles, Los Angeles (S.A.H.), and Kaiser Permanente, Northern California, Vallejo (L.F.) — all in California; the...
ORCID: Litton, Jennifer K.
Rugo, Hope S.
Ettl, Johannes
Hurvitz, Sara A.
Lee, Kyung-Hun
Fehrenbacher, Louis
Yerushalmi, Rinat
Mina, Lida A.
Im, Young-Hyuck
Quek, Ruben G.W.
Tudor, Iulia C.
Blum, Joanne L.
Venue: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Published: 2018-08-23
Volume: 379
Issue: 8
Pages: 753-763
ISSN: 0028-4793 (ISSN-L)
1533-4406
DOI: 10.1056/nejmoa1802905
PMC: PMC10600918
OpenAlex: W2886477543
Cited by: 2,175
References: 14
Citations by year: 2026: 195 · 2025: 241 · 2024: 254 · 2023: 312 · 2022: 356 · 2021: 319 · 2020: 280 · 2019: 195 · 2018: 20
FWCI: 76.58
Type: journal article
Language: en
Open access: green
www.ncbi.nlm.nih.gov
Licence: www.nejmgroup.org/legal/terms-of-use.htm (vor)
Locations: New England Journal of Medicine (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
eScholarship (California Digital Library) (submittedVersion)
mediaTUM (Technical University of Munich) (submittedVersion)
Funders: Pfizer
Topics: Health Sciences › Medicine › Oncology › PARP inhibition in cancer therapy
Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › BRCA gene mutations in cancer
Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
Keywords: PARP inhibitors, advanced breast cancer, germline BRCA1 mutation, germline BRCA2 mutation, progression-free survival, objective response rate, hematologic adverse events, anemia, patient-reported outcomes, quality of life, single-agent chemotherapy, capecitabine, eribulin, gemcitabine, vinorelbine, PARP inhibitor resistance, PARP inhibitor combination therapy
MeSH terms: Poly(ADP-ribose) Polymerase Inhibitors, Patient Reported Outcome Measures, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Breast Neoplasms, Female, Humans, Middle Aged, Phthalazines, Quality of Life, Survival Analysis, Germ-Line Mutation, Disease-Free Survival, Genes, BRCA1, Genes, BRCA2

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks